Six Genetic Variants of Brugada Syndrome Identified in Malaysia
A recent study reveals six SCN5A gene variants linked to Brugada syndrome among Malaysian adults, shedding light on genetic diversity.
Six variants in the SCN5A gene were identified in Malaysian patients with Brugada syndrome.
The study involved 40 patients, revealing significant clinical diversity in symptoms.
Findings support the need for genetic testing in assessing risk and family screening.
A groundbreaking study has uncovered six genetic variants associated with Brugada syndrome in Malaysian adults, specifically within the SCN5A gene. This research highlights the genetic diversity and varying clinical presentations of this inherited cardiac condition, which is linked to ventricular arrhythmias and sudden cardiac death. The findings are particularly significant given the limited genetic data available on this condition in Malaysia, despite its notable prevalence in Southeast Asia.
The research was conducted through a multicenter case-control study aimed at characterizing genetic variants related to Brugada syndrome and detailing the clinical phenotypes observed in Malaysian adults. Patients were recruited from various tertiary cardiology centers across the country, with diagnoses confirmed through electrocardiograms (ECGs) that displayed Brugada patterns, including Types 1, 2, and 3. Healthy controls were selected based on normal ECG findings and no family history of sudden cardiac death.
In total, 40 patients participated in the study, allowing for an initial exploration of genetic variations and clinical characteristics within this demographic. The analysis revealed six variants in the SCN5A gene, categorized into pathogenic, likely pathogenic, uncertain significance, and benign classifications. Notably, the p.Arg965Cys variant was found in 12.5% of the cases, indicating its significance within the population studied. Clinical symptoms varied widely, with palpitations reported by 47.5% of patients, chest pain in 37.5%, presyncope in 35%, syncope in 32.5%, and dizziness in 30%. Seizure-like episodes were less frequent, occurring in only 7.5% of patients.
These findings underscore the considerable clinical heterogeneity present among individuals with Brugada syndrome and the identification of multiple genetic variants with varying clinical implications. The researchers emphasized that this study represents the first comprehensive genetic investigation of Brugada syndrome in Malaysia, filling a critical gap in the understanding of this condition among affected adults. The identification of clinically significant SCN5A variants suggests that genetic testing could enhance clinical assessments and familial screening processes.
While the study did not confirm whether individual variants could independently predict the risk of ventricular arrhythmias or sudden cardiac death, the results advocate for the integration of genetic testing into risk stratification and family screening strategies. This research paves the way for the advancement of precision cardiology approaches in Malaysia, potentially improving patient outcomes and management strategies in the future.
